Latest Biotech Startup Funding Rounds
Financing for drug discovery, therapeutics and biological technologies, with the development context behind each round.
- Rounds
- 153 Jul 18 – Oct 15, 2026
- Disclosed funding
- $5.2B 123 disclosed amounts
- Median round
- $20M Of disclosed amounts
| Company | Amount | Round | Sector | Country | Investors | Announced |
|---|---|---|---|---|---|---|
| A AitiologicCompany profile A precision-medicine company developing liquid-biopsy tests that interpret cell-free DNA signals for early disease risk assessment. A precision-medicine company developing liquid-biopsy tests that interpret cell-free DNA signals for early disease risk assessment. | €6.4M | Seed | Biotech | Austria | Investors | |
| RI RegCell, Inc.Company profile RegCell is developing cell therapies for autoimmune disease by epigenetically reprogramming pathogenic conventional T cells into stable regulatory T cells, aiming to restore immune tolerance without gene engineering; its platform is advancing toward clinical development. RegCell is developing cell therapies for autoimmune disease by epigenetically reprogramming pathogenic conventional T cells into stable regulatory T cells, aiming to restore immune tolerance without gene engineering; its platform is advancing toward clinical development. | $44M | Series A | Biotech | United States | Investors | |
| RI ReEmerge, Inc.Company profile ReEmerge is developing Cognitive Network Restoration Therapy (CNRT) for people with chronic cognitive impairment after brain injury. The treatment targets underactive but viable neural circuits in the central thalamus to restore function across disrupted brain networks; the company is advancing this restorative approach through clinical development. ReEmerge is developing Cognitive Network Restoration Therapy (CNRT) for people with chronic cognitive impairment after brain injury. The treatment targets underactive but viable neural circuits in the central thalamus to restore function across disrupted brain networks; the company is advancing this restorative approach through clinical development. | $37M | Series A | Biotech, Healthtech | United States | Investors | |
| E EvvyCompany profile Evvy combines at-home vaginal microbiome testing with clinician-reviewed results, personalized next steps and optional treatment and coaching for women’s health. Evvy combines at-home vaginal microbiome testing with clinician-reviewed results, personalized next steps and optional treatment and coaching for women’s health. | $40M | Series B | Biotech, Healthtech | United States | Investors | |
| AB AOI Biosciences, Inc.Company profile A biotechnology company developing antibody diagnostics and drug-discovery methods for difficult protein targets. A biotechnology company developing antibody diagnostics and drug-discovery methods for difficult protein targets. | Undisclosed | Equity issuance and secondary transferUndisclosed | Biotech | Japan | Investors | |
| FL Ferm LabsCompany profile Ferm Labs develops fermentation-based flavour ingredients for food manufacturers, using fermentation science to deepen savoury taste and help reformulate products with less salt and fewer additives. Ferm Labs develops fermentation-based flavour ingredients for food manufacturers, using fermentation science to deepen savoury taste and help reformulate products with less salt and fewer additives. | €3M | Seed | Biotech, Foodtech | Switzerland | Investors | |
| SB Shennon BiotechnologiesCompany profile Shennon Biotechnologies is developing precision T-cell engager immunotherapies for solid tumors. Shennon Biotechnologies is developing precision T-cell engager immunotherapies for solid tumors. | $12M | FundingUndisclosed | Biotech | United States | Investors | |
| AB Athernal BioCompany profile Targeted immunotherapies aim to stop blood cancers by treating high-risk clonal hematopoiesis before malignancy emerges. Targeted immunotherapies aim to stop blood cancers by treating high-risk clonal hematopoiesis before malignancy emerges. | ~£700K | GrantUndisclosed | Biotech | United Kingdom | Investors | |
| E EthrisCompany profile Ethris develops inhaled mRNA therapeutics and vaccines for respiratory diseases, using proprietary RNA stabilization and nanoparticle delivery platforms. Ethris develops inhaled mRNA therapeutics and vaccines for respiratory diseases, using proprietary RNA stabilization and nanoparticle delivery platforms. | €30M | HERA Invest financingUndisclosed | Biotech | Germany | Investors | |
| CT Connecta TherapeuticsCompany profile Connecta Therapeutics develops small-molecule treatments for neurological disorders, including CTH120, a clinical-stage candidate for Fragile X syndrome. Connecta Therapeutics develops small-molecule treatments for neurological disorders, including CTH120, a clinical-stage candidate for Fragile X syndrome. | €3.1M | Clinical development financingUndisclosed | Biotech | Spain | Investors |
Active investors in this selection
All investors →Ranked by rounds participated in · From Jul 18, 2026
- 1Eli Lilly and Company
BigHat Biosciences, Circle Pharma, Inc., Moonwalk Biosciences
10rounds0led - 2RA Capital Management
Circle Pharma, Inc., Solstice Oncology, Superluminal Medicines
8rounds2led - 3Y Combinator (YC)
Molagri, Sensible Biotechnologies, WonderTx
6rounds0led - 4Catalio Capital Management
BigHat Biosciences, Basecamp Research, Enveda
6rounds2led - 5Oxford Science Enterprises
OMass Therapeutics, ReEmerge, Inc., Vivid Dx
5rounds0led
Latest digests
Archive →Explore published rounds while the next edition is being prepared.